Page last updated: 2024-11-06

mitomycin and Myeloproliferative Disorders

mitomycin has been researched along with Myeloproliferative Disorders in 1 studies

Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.

Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.

Research Excerpts

ExcerptRelevanceReference
"Two hundred forty-one patients with unresectable gastric adenocarcinoma were entered, between December 1978 and March 1981, into a prospectively randomized comparison of three chemotherapy regimens to identify therapeutic activity and determine patient tolerability: (1) 5-fluorouracil plus Adriamycin (FA); (2) FA plus methyl-CCNU (FAMe); and (3) FA plus mitomycin C (FAMi)."5.05Randomized study of combination chemotherapy in unresectable gastric cancer. The Gastrointestinal Tumor Study Group. ( , 1984)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Trials

1 trial available for mitomycin and Myeloproliferative Disorders

ArticleYear
Randomized study of combination chemotherapy in unresectable gastric cancer. The Gastrointestinal Tumor Study Group.
    Cancer, 1984, Jan-01, Volume: 53, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubici

1984